TCM
BPMC

TimesSquare Capital Management’s Blueprint Medicines BPMC Stock Holding History

TimesSquare Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-243,899
Closed -$15.6M – 193
2022
Q1 		$15.6M Sell
243,899
-1,143,431
-82% -$82.1M 0.17% 161
2021
Q4 		$149M Sell
1,387,330
-81,215
-6% -$8.5M 1.32% 5
2021
Q3 		$151M Sell
1,468,545
-106,550
-7% -$9.92M 1.32% 6
2021
Q2 		$139M Buy
1,575,095
+146,025
+10% +$13.4M 1.13% 12
2021
Q1 		$139M Buy
1,429,070
+183,665
+15% +$18.3M 1.19% 8
2020
Q4 		$140M Buy
1,245,405
+145,270
+13% +$15.3M 1.13% 9
2020
Q3 		$102M Buy
1,100,135
+331,285
+43% +$25.5M 0.95% 18
2020
Q2 		$60M Buy
768,850
+2,305
+0.3% +$156K 0.57% 64
2020
Q1 		$44.8M Sell
766,545
-190,885
-20% -$12.3M 0.53% 69
2019
Q4 		$76.7M Buy
957,430
+107,610
+13% +$8.06M 0.68% 42
2019
Q3 		$62.4M Buy
849,820
+49,800
+6% +$4.3M 0.55% 76
2019
Q2 		$75.5M Sell
800,020
-54,600
-6% -$4.51M 0.58% 58
2019
Q1 		$68.4M Sell
854,620
-147,020
-15% -$10.9M 0.53% 74
2018
Q4 		$54M Sell
1,001,640
-39,400
-4% -$2.39M 0.47% 92
2018
Q3 		$81.3M Sell
1,041,040
-29,900
-3% -$2.08M 0.54% 65
2018
Q2 		$68M Buy
1,070,940
+234,565
+28% +$18.7M 0.45% 87
2018
Q1 		$76.7M Sell
836,375
-268,855
-24% -$23.2M 0.52% 72
2017
Q4 		$83.3M Buy
1,105,230
+237,530
+27% +$16.7M 0.55% 67
2017
Q3 		$60.5M Buy
867,700
+307,700
+55% +$16.4M 0.41% 95
2017
Q2 		$28.4M Buy
+560,000
New +$23.8M 0.18% 188

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

TimesSquare Capital Management's BPMC Position: Q2 2022 in Review

TimesSquare Capital Management sold out of Blueprint Medicines (BPMC) in Q2 2022, closing a stake of 243,899 shares — an estimated $15.6M sold.

TimesSquare Capital Management first reported a position in BPMC in Q2 2017 and held it in 20 quarters. The position peaked at $151M in Q3 2021. 237 funds tracked by Wall St. Rank hold BPMC as of Q2 2022.

  • TimesSquare Capital Management reported no remaining Blueprint Medicines position as of Q2 2022 after selling out during the quarter.
  • TimesSquare Capital Management sold 243,899 Blueprint Medicines shares in Q2 2022, an estimated $15.6M.
  • TimesSquare Capital Management first reported a position in Blueprint Medicines in Q2 2017 and held it in 20 quarters.
  • TimesSquare Capital Management's Blueprint Medicines position peaked at $151M in Q3 2021.
  • 237 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2022.

Based on TimesSquare Capital Management's 13F filing for Q2 2022, filed 5 Aug 2022.